Bentham Science Newsletter

Oncology Spotlight | Bentham Science

In this issue, we take a look at recent developments in cancer research and therapy

Atractylon - A Potential Compound for Liver Cancer

A promising new study has revealed the antitumor potential of Atractylon, a natural bioactive compound derived from medicinal plants of the genus Atractylodes. This plant genus has a long history in traditional East Asian medicine, where it is frequently prescribed to treat influenza and gastrointestinal ailments. Utilizing advanced quantitative proteomics and functional cellular assays, the research team demonstrated that Atractylon successfully halts the proliferation of aggressive liver cancer cells. The compound actively arrests the cell cycle at the critical G2/M phase, which subsequently suppresses the ability of the cancer cells to migrate and invade surrounding healthy tissues.

Crucially, the study revealed that Atractylon achieves these impressive antitumor effects by triggering ferroptosis, a unique form of programmed cell death driven by iron accumulation. The researchers discovered that Atractylon significantly upregulates the expression of SLC39A14 (also known as ZIP14), a specialized metal transporter located on the cell membrane. By boosting SLC39A14 levels, the compound facilitates a massive influx of intracellular iron (Fe2+) and reactive oxygen species (ROS), resulting in devastating lipid peroxidation that destroys the cancer cells from within. When researchers experimentally knocked down this specific transporter, the therapeutic effectiveness of the compound was severely diminished. Ultimately, these findings highlight Atractylon as a promising candidate for next-generation liver cancer drugs, offering a compelling bridge between traditional herbal wisdom and modern oncology.

Long-Lasting Nanoparticles Shine Brighter in Tumor Imaging

In a new study, Scientists have successfully synthesized tiny, specialized drug-delivery vehicles known as PEGylated liposomes. By encapsulating albumin within these microscopic fat bubbles and labelling them with Indium-111 (¹¹¹In-oxine) — a radioactive tracer — the team created a highly stable imaging agent. The strategic addition of polyethylene glycol (PEGylation) shields the liposomes, reducing their volume of distribution and slowing down their clearance by the body's immune system. This structural defense allows the nanoparticles to circulate through the bloodstream for an extended period, maximizing their opportunities to find and penetrate tumors.

To test the real-world efficacy of this formulation, the researchers evaluated its performance in mice bearing C26 colon tumors using both quantitative radioactivity tracking and qualitative gamma camera scans. The results were highly encouraging: the radiolabelled liposomes naturally concentrated heavily within the tumor sites, alongside expected metabolic organs like the liver, spleen, and kidneys. Remarkably, even after the formulation began clearing from the general bloodstream, it remained highly concentrated as visible "hot spots" at the tumor sites for up to 96 hours. This exceptional 4-day stability highlights the formulation's immense potential to be transformed into a clinical tool, offering oncologists a powerful new window for long-term tumor tracking.

The Dark Side of Vitamin B2: How Riboflavin Shields Cancer Cells

A study conducted by the researchers at the Rudolf Virchow Centre in the Julius-Maximilians-Universität Würzburg reveals that vitamin B2 metabolism actively shields tumors from ferroptosis, a specialized form of programmed cell death driven by iron-dependent oxidative stress. While healthy cells use programmed cell death to eliminate damaged tissue safely, aggressive cancer cells frequently exploit metabolic pathways to avoid this fate. Central to this survival mechanism is a protein called FSP1, which naturally prevents unwanted cell death. The research team discovered that vitamin B2 plays a vital role in supporting and fuelling FSP1 activity, essentially giving tumors an armor coating against the body’s natural defense systems.

Using advanced genome editing and cancer cell models, the scientists demonstrated that limiting vitamin B2 availability drastically increased the tumor’s vulnerability to ferroptosis. Because no approved drugs currently target this specific riboflavin pathway, the team successfully tested a natural, vitamin B2-like bacterial compound called roseoflavin. Even at exceptionally low concentrations, roseoflavin bypassed the protective shield and effectively triggered mass cancer cell death in laboratory tests. This proof-of-concept discovery opens an interesting new frontier in oncology that paves the way for future therapies designed to starve tumors of their metabolic armor.

How a Notorious Cancer Protein Rebuilds Damaged DNA

Many aggressive tumors are associated with deregulation of the MYC transcription factor. For decades, scientists have blamed MYC for driving this growth. MYC is infamous in oncology for acting as a cellular accelerator, switching on specific genes that cause cells to grow and metabolize uncontrollably. However, a groundbreaking study from Oregon Health & Science University has uncovered a surprising, non-traditional trick up MYC's sleeve: it doesn't just help tumors grow, it actively repairs them.

Published in the journal Genes and Development, the research reveals that when cancer cells experience severe DNA damage — whether from rapid growth or aggressive clinical treatments — a modified form of the MYC protein abandons its usual role. Instead, it rushes directly to the sites of critical DNA breaks. There, MYC functions as an emergency repair supervisor, physically gathering and recruiting vital repair machinery to restore the broken genetic code.

By actively promoting DNA repair, this modified protein effectively shields tumor cells from treatment-induced death. The team found that cells with highly active MYC repaired damage far more efficiently, an effect particularly pronounced in pancreatic cancer, one of the deadliest and most treatment-resistant forms of the disease. Cancers with high MYC activity directly correlated with worse patient outcomes. Fortunately, this discovery provides a clear target. Researchers are already testing a first-in-class MYC inhibitor in clinical trials, offering hope for therapies that can dismantle cancer’s emergency repair system.

Light-Based Therapy Shows Promise for Inoperable Airway Tumors

Managing inoperable central tracheobronchial malignant tumors presents a severe clinical challenge, as these airway malignancies heavily impact breathing and overall quality of life. While photodynamic therapy (PDT), a treatment combining light-sensitive drugs with specific laser wavelengths to destroy cancer cells holds considerable potential, clinical data regarding its use in Chinese populations has historically been scarce. To fill this gap, a new preliminary study evaluated both the real-world therapeutic efficacy and safety profile of PDT for patients facing these central airway obstructions.

The clinical study monitored nine patients with central tracheobronchial malignant tumors who underwent PDT and were followed for over two years. Researchers focused on primary endpoints of clinical efficacy and safety, alongside secondary endpoints tracking one-year overall survival (OS), two-year OS, and recurrence-free survival (RFS). The results were highly encouraging: six of the nine patients exhibited sustained clinical stability for at least one year. Following the treatment, patients experienced a statistically significant improvement in both their direct clinical symptoms and their overall quality of life (t = 5.57, P < 0.0001).

Survival outcomes further highlighted the therapy's clinical value. The one-year overall survival rate reached 88.9%, and the two-year survival rate stood at 77.8%. The mean recurrence-free survival across the group was 15.9 \pm 10.5 months, with two patients diagnosed with adenoid cystic carcinoma not yet even reaching their average recurrence window. Crucially, the treatment proved remarkably safe; adverse effects were mild and self-limiting, consisting only of two minor grade 1 photosensitivity reactions and one instance of localized bronchial scarring, with no serious complications reported. While the small, single-center sample size means larger studies are needed for broad validation, these findings establish PDT as a highly viable, well-tolerated intervention that delivers favorable survival outcomes for central airway malignancies.